Clinical Data with 4SC's Compound Vidofludimus in IBD Published Online
News Nov 06, 2012
4SC AG has announced that data from its clinical Phase II study with Vidofludimus in patients with inflammatory bowel disease (IBD), which was completed and reported last year, have been published online in a peer-reviewed article in Journal of Crohns & Colitis (18 October 2012, http://dx.doi.org/10.1016/j.crohns.2012.09.016, article in press, published online ahead of print).
In the open-label, clinical Phase IIa study, vidofludimus had been investigated in steroid-dependent patients with Crohn's disease and Ulcerative colitis.
The compound was safe and well tolerated and showed a positive response rate in 88.5% of the patients by completely or partially reducing patients' dependence on cortico-steroid drugs.
Dr. Ulrich Dauer, CEO of 4SC AG said: 'The publication of the convincing clinical data in a peer-reviewed article in the Journal of Crohns & Colitis emphasises the therapeutic potential of vidofludimus as a novel therapy of autoimmune diseases, in particular in IBD. This also reinforces our ambitions for our planned clinical Phase IIb study in Crohn's disease which we intend to conduct preferably together with a partner.'
2nd AI Pharma Innovation: Drug Discovery 2019 Summit
Feb 27 - Feb 28, 2019
5th International Congress on Epigenetics & Chromatin
Aug 22 - Aug 23, 2019
14th World Congress on Medicinal Chemistry and Drug Design
Jun 10 - Jun 11, 2019
International Conference on e-Health and Healthcare Innovations
May 08 - May 09, 2019